Innohep

Tinzaparin Sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a sterile solution for subcutaneous use. It is employed to prevent and treat venous thromboembolism in surgical and medical patients.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep, a low molecular weight heparin, acts on the coagulation cascade to manage thromboembolic disorders. - Prevention of deep vein thrombosis (DVT) in surgical patients: reduces the risk of clot formation after orthopedic or abdominal surgery. - Treatment of acute deep vein thrombosis: facilitates clot resolution and prevents propagation. - Treatment and secondary prevention of pulmonary embolism: lowers recurrence risk of embolic events.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Injection site erythema: mild redness at the injection site. - Injection site pain or bruising: localized discomfort or discoloration. - Minor bleeding: such as gum or nosebleeds. - Thrombocytopenia (mild): slight reduction in platelet count.

Serious or Rare Side Effects: - Major bleeding: gastrointestinal or intracranial hemorrhage. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet activation. - Elevated liver enzymes: abnormal hepatic function tests. - Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures.

Careful assessment is required before initiating therapy. - Renal impairment: adjust dose or monitor anti‑Xa activity. - History of heparin‑induced thrombocytopenia: contraindicated. - Concurrent anticoagulants or antiplatelet agents: increased bleeding risk. - Recent surgery or trauma: evaluate bleeding risk before injection. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin may interact with several drug classes, influencing bleeding risk.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): high risk of severe bleeding. - Systemic thrombolytics (e.g., alteplase): potentiates hemorrhagic complications. - NSAIDs or antiplatelet agents (e.g., aspirin, clopidogrel): additive bleeding tendency.

Moderate Interactions (Monitor Closely): - Concurrent heparin products: monitor anti‑Xa levels to avoid over‑anticoagulation. - Renally cleared drugs (e.g., aminoglycosides): assess renal function regularly. - Corticosteroids: may increase mucosal bleeding; observe for signs of hemorrhage.